Riverhead Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Riverhead Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$22K	Hold	270	–	–	﹤0.01%	1465
2019 Q2	$20K	Sell	270 -13	-5%	-$997	﹤0.01%	1495
2019 Q1	$26K	Buy	283 +64	+29%	+$5.35K	﹤0.01%	1463
2018 Q4	$16K	Sell	219 -1,571	-88%	-$121K	﹤0.01%	1472
2018 Q3	$157K	Sell	1,790 -575	-24%	-$57.8K	0.01%	1275
2018 Q2	$233K	Buy	2,365 +1,565	+196%	+$155K	0.01%	1008
2018 Q1	$95K	Buy	+800	New	+$103K	﹤0.01%	1351

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Riverhead Capital Management's ALNY Position: Q3 2019 in Review

Riverhead Capital Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2019 at 270 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Riverhead Capital Management first reported a position in ALNY in Q1 2018 and has held it in 7 quarters since. The position peaked at $233K in Q2 2018. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Riverhead Capital Management held 270 shares of Alnylam Pharmaceuticals worth $22K as of Q3 2019.
Riverhead Capital Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2019.
Alnylam Pharmaceuticals made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1465 holding.
Riverhead Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Riverhead Capital Management's Alnylam Pharmaceuticals position peaked at $233K in Q2 2018.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.